Background: Juvenile detention centers offer public health practitioners an opportunity to gain access to large numbers of adolescents at risk for chlamydia and gonorrhea.
chlamydia, facilitate HIV transmission. 3 Lifetime medical costs associated with chlamydial and gonococcal infections in 15-to 24-year-olds in 2000 were estimated at $325.4 million. 4 Screening for chlamydia and gonorrhea has been shown to be a cost-effective strategy for preventing adverse reproductive health consequences. 5 Chlamydia and gonorrhea rates are highest in adolescent women aged 15 to 19 years and highest in men aged 20 to 24 years. 1 The Centers for Disease Control and Prevention (CDC) recommends chlamydia screening for pregnant women, annual screening for sexually active adolescents, for women aged 20 to 25, and for older women with risk factors (e.g., those who report new or multiple sex partners). 6 The United States Preventive Task Force recommends routine chlamydia screening for all sexually active women aged 25 years and younger and gonorrhea screening for high-risk asymptomatic women (i.e., commercial sex workers, persons with a history of repeated episodes of gonorrhea, and women under the age of 25 years reporting 2 or more sex partners in the past year). 7 There are no guidelines for screening men.
Urine-based nucleic acid amplification tests for detecting chlamydia and gonorrhea have facilitated screening for these infections in nontraditional settings such as juvenile detention centers. While there are few reports of the prevalence of gonorrhea in this population or of coinfection with chlamydia in incarcerated youth, a high prevalence of chlamydia has been found. 8 -11 Based on these findings, screening incarcerated adolescent females for chlamydia has been recommended by the CDC. 12 In 2002, there were 1.4 million arrests of persons under the age of 18 years in the United States, 13 including approximately 1.0 million males and 400,000 females. However, the number of incarcerated adolescents that are routinely screened for these infections is unknown.
This purpose of this analysis was to assess the prevalence and rate of coinfection of chlamydia and gonorrhea in adolescents entering 14 juvenile detention centers in 6 metropolitan areas with diverse chlamydia and gonorrhea rates from 1997 to 2002 and to identify demographic characteristics associated with these infections.
Methods
In 1996, the CDC began monitoring chlamydia and gonorrhea prevalence in sentinel corrections populations through the Jail STD Prevalence Monitoring Project. 10 Information on arrestee age, race/ethnicity, laboratory test type, and chlamydia and gonorrhea test results is collected electronically and submitted to the CDC on a quarterly and annual basis. State and local health department officials collaborate with juvenile detention center medical staff to assure treatment, counseling, and sex-partner follow-up.
We performed a cross-sectional analysis of chlamydia and gonorrhea test data submitted to the Jail STD Prevalence Monitoring Project from January 1, 1997 The facilities included in this analysis implemented a protocol of routine urine-based screening for chlamydia and gonorrhea upon entry or at the time of first medical examination at the facility. Testing was conducted on a voluntary basis. Medical staff, employed by the juvenile detention centers, obtained urine specimens and collected demographic information from incarcerated adolescents. These staff also collected information from males on the occurrence of discharge and dysuria. A variety of commercially available nucleic acid amplification tests, including the Abbott LCx assay (Abbott Laboratories, Abbott Park, IL), Becton Dickinson ProbeTec ET assay (Becton, Dickinson and Company, Franklin Lakes, NJ), Gen-Probe Transcription Mediated Amplification and Aptima Combo-2 test (Gen-Probe, Incorporated, San Diego, CA) was used to test for chlamydia and gonorrhea. The Roche Amplicor PCR (Roche Diagnostics Corporation, Basel, Switzerland) was used to test for chlamydia. We analyzed data on demographic characteristics, chlamydia and gonorrhea test results, date of test, screening venue, and symptom status (symptom data were available only for males screened in California).
Chlamydia and Gonorrhea Prevalence
We estimated chlamydia and gonorrhea prevalence by dividing the number of positive test results by the total number of test results that were either positive or negative (inconclusive and unsatisfactory test results were excluded from the denominator). We calculated chlamydia and gonorrhea prevalence by sex for each age group (12-14 years, 15-16 years, 17-18 years), racial or ethnic group (Asians, non-Hispanic blacks, non-Hispanic whites, Hispanics, and other), geographic area, and year (1997) (1998) (1999) (2000) (2001) (2002) . We used SAS version 8 (SAS Institute, Inc, Cary, NC) to assess differences in proportions with the 2 and the Cochran-MantelHaenszel tests.
Chlamydia and Gonorrhea Coinfection
We calculated chlamydia prevalence for females and males that were infected with gonorrhea. Conversely, we calculated gonorrhea prevalence of adolescents infected with chlamydia. We restricted these analyses to include sites where greater than 80% of female and male detainees that were tested for chlamydia were also tested for gonorrhea.
Results

Chlamydia Prevalence
From January 1, 1997, to December 31, 2002, there were 131,915 chlamydia tests performed in 14 juvenile detention centers. Of these, 33,619 (25%) chlamydia tests were on females, and 98,296 (75%) were on males. Fifty-three percent of the tests performed were on non-Hispanic blacks, 28% of tests were on Hispanics, and non-Hispanic whites accounted for 13% of tests. Almost half (49%) of persons tested were 15 or 16 years old, 29% were 17 or 18 years old, 21% were 12 to 14 years old. Most of the tests were done in Los Angeles (48%); smaller proportions were done in Alameda County, CA (15%), Maryland (13%), San Francisco (9%), NY (9%), and Atlanta (6%).
Of the 131,915 tests, 11,024 (8.4%) were positive for Chlamydia trachomatis. The prevalence of chlamydia was approximately 2.5 times higher in females than in males (15.6% versus 5.9%, P Ͻ 0.01) and was highest in blacks (9.9%), followed by Hispanics (7.3%) and whites (5.8%) ( Table 1) . Chlamydia prevalence in females did not vary significantly by age group; however, in males, prevalence was associated with older age ( 2 test for trend; P Ͻ 0.01). The prevalence of chlamydia varied significantly by project site in females (10.0%-20.0%) and males (3.2%-8.0%); differences persisted after controlling for both race and age group (Cochran-Mantel-Haenszel test; females P Ͻ 0.01; males P Ͻ 0.01).
Gonorrhea Prevalence
There were 71,074 gonorrhea tests performed, 29,551 (40%) in females and 41,523 (60%) in males. Tests were on non-Hispanic blacks (61%), Hispanics (18%), and non-Hispanic whites (17%). Almost half (49%) of persons tested were 15 to 16 years old; 29% were 17 or 18 years old, and 22% were 12 to 14 years old. The gonorrhea testing data came from Los Angeles (31%); Alameda County, CA (28%); Maryland (20%); San Francisco (12%); and Atlanta (11%).
Of the 71,074 tests, 2065 (2.9%) were positive for N gonorrhoeae. The demographic characteristics of youth at greatest risk for gonococcal infection closely mirrored those at greatest risk for chlamydial infection. Gonorrhea prevalence was 4 times higher in females than in males (5.1% versus 1.3%, P Ͻ 0.01) ( Table 2 ). In females, gonorrhea prevalence was 3 times higher in blacks compared to nonblacks (7.5% versus 2.4%, P Ͻ 0.01). Black males were 4.5 times more likely than males of other races to have gonorrhea (1.8% versus 0.4%, P Ͻ 0.01). Gonorrhea prevalence in females did not vary significantly by age group; however, among males, prevalence increased with age ( 2 for trend; P Ͻ 0.01). Gonorrhea prevalence varied significantly by project site among males (0.8%-1.9%) and females (4.3%-8.8%); differences persisted after controlling for both race and age group (CochranMantel-Haenszel test; females P Ͻ 0.01; males P Ͻ 0.01).
Chlamydia and Gonorrhea Coinfection
There were 28,375 females tested for both chlamydia and gonorrhea, and 806 (2.8%) females were coinfected; of 30,135 males who 
Symptoms
Three sites (Alameda, CA; Los Angeles, CA; San Francisco, CA) routinely collected data on the occurrence of urethral discharge and dysuria in males. A total of 79 (0.16%) of 47,682 males reported having urethral discharge, and 219 (0.46%) reported having dysuria. Seventeen of 173 (9.8%) males with gonococcal infection reported either discharge or dysuria, and only 20 of 854 (2.3%) males with chlamydial infection reported either symptom.
Discussion
These data indicate that screening incarcerated adolescents for chlamydia and gonorrhea is feasible and productive. The analysis presented here represents the largest number of incarcerated youth on whom chlamydia and gonorrhea prevalence data have been systematically collected. The prevalence of chlamydia in female adolescents in these 14 juvenile detention centers was very high over the 6-year period. However, the overall community case rates, based on the number of reported cases, among females in these 6 jurisdictions were variable (ranging from 478 per 100,000 in San Francisco to 1580 per 100,000 in Baltimore), 1 suggesting that even in areas with relatively low chlamydia case rates, the prevalence in incarcerated adolescent females may be high. Chlamydia prevalence in incarcerated males in these juvenile detention centers was generally at least half that found in females but was 6% or greater in 4 of the 6 areas. Gonorrhea prevalence was also high in incarcerated females but substantially lower in males.
Our finding of high chlamydia and gonorrhea prevalence in incarcerated female adolescents is consistent with the findings of other screening programs of adolescents in nontraditional settings. 14 -17 High chlamydial infection rates in female arrestees have been observed in corrections facilities in Chicago (27%), Birmingham (22%), Baltimore (5.9%), and Houston (28.1%). 11, 18, 19 The median chlamydia prevalence in incarcerated adolescent females in our analysis (16.8%) is 3 times higher than the median prevalence (5.6%) in 15-to 24-year-old females attending selected family planning clinics in 2002. 1 The median gonorrhea prevalence in incarcerated females in our analysis (5.4%) is 5 times higher than the median prevalence in 15-to 24-year-old females in selected family planning clinics (0.9%). 1 These data suggest that *P Ͻ 0.01, 2 ; significant differences among racial/ethnic groups (males and females). †Includes American Indian and "other" races. ‡P Ͻ 0.01, 2 for trend; significant differences among age groups (males). §P Ͻ 0.01, 2 ; significant differences among areas (males and females). ʈIncludes the city of Oakland. There are few published reports of chlamydia and gonorrhea prevalence in males screened in settings outside of STD clinics. A study among US Army recruits found a chlamydia prevalence of 5.3% and a gonorrhea prevalence of 0.6%. 20 In 1998, Oh et al. 21 reported a chlamydia preva- lence of 6.9% and a gonorrhea prevalence of 4.5% in incarcerated adolescent males; in 2001, Risser et al. 19 found 9.6% of incarcerated adolescent males tested positive for chlamydia. In the 6 areas included in our analysis, the prevalence of chlamydia in incarcerated adolescent males ranged from 3.2% to 8.0%. In the 3 sites that collected information on symptoms, over 95% of males with chlamydia were asymptomatic, and over 90% of males with gonorrhea were asymptomatic, suggesting that testing based on clinically defined symptoms would fail to identify the great majority of these infections. Our estimates are among the highest chlamydia positivity rates reported in adolescent males and suggest that STD control programs expanding chlamydia screening to males should consider this population a priority.
A large proportion of females and males with gonorrhea also were infected with chlamydia (54% in females and 51% in males), supporting the CDC recommendation that patients treated for gonococcal infection also be treated routinely with a regimen effective against uncomplicated genital C trachomatis infection. 6 Studies in other settings have documented high coinfection rates as well. Dicker et al. 22 reported that a median of 46% of gonorrheapositive females aged 15 to 19 years in family planning clinics were coinfected with chlamydia, and 45.5% were coinfected in STD clinics. We found that a large proportion of females and males with chlamydia also were infected with gonorrhea (18% in females and 13% in males). In areas with limited resources, this finding may support the implementation of reflexive testing for gonorrhea upon a positive chlamydia laboratory test.
There are limitations to the approach used in our analysis. The proportion of adolescents screened among the total number admitted to these facilities is unknown. If higher-risk adolescents were screened at a greater rate than lower-risk adolescents, then our prevalence estimates may overestimate the true prevalence among all arrestees. We are unable to comment on prevalence trends in these populations since the number of adolescents screened in many sites increased over the study period, with the programs becoming a routine part of health care services.
We estimate that implementing national screening programs in juvenile detention centers would detect 56,384 chlamydial infections and 18,433 gonococcal infections in females annually and 52,683 chlamydial infections and 11,608 gonococcal infections in males annually. These estimates are based on the overall chlamydia and gonorrhea prevalences found in this study, the 2002 adolescent incarceration rates, 13 and the assumption that 90% of incarcerated female and male adolescents are sexually active 21, 23, 24 and therefore eligible for screening.
The high chlamydia prevalence in incarcerated females in these 14 juvenile detention centers over the 6-year study period supports the implementation of screening in juvenile detention centers as a method to reach high-risk populations that may have limited access to regular health care. Similarly, the markedly high gonorrhea prevalence in incarcerated females suggests that routine screening for gonorrhea in these settings should be considered. Implementing these programs may require that resources be shifted from other, less productive screening sites.
